Thyrocare Technologies promoter Docon Technologies Private Limited has released a pledge on 1,75,00,000 equity shares of the diagnostics firm. Catalyst Trusteeship Limited, acting as the Debenture Trustee, executed the release on August 11, 2026. The disclosure was made to stock exchanges on August 13, 2026, pursuant to Regulations 29(2), 31(2), and 31(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The release lowers the proportion of encumbered shares held by Docon Technologies from 60.92% to 49.93% of Thyrocare's total share capital. Docon continues to hold a total of 9,69,69,696 equity shares, representing 60.92% of the company's voting capital and 60.75% of its diluted share capital. The unpledged portion of the promoter's holding now stands at 1,75,00,000 shares.

Encumbrance details

The shares were originally pledged as security for Non-Convertible Debentures (NCDs) issued by API Holdings Limited, the holding company of Docon Technologies. As of the reporting date, the outstanding principal amount of these NCDs is ₹10,500 million. The pledge release does not alter the total debt obligation but reduces the collateral coverage ratio for the secured lenders.

Lender concentration

The disclosure provides a detailed breakdown of the ₹10,500 million outstanding NCD principal among various holders. Key holders include:

• 360 One Prime Limited: ₹4,870.25 million
• Tata Capital Limited: ₹2,843.75 million
• Bennett Coleman and Company Limited: ₹437.50 million
• Poonawalla Fincorp Limited: ₹918.75 million
• J Kumar Infra Projects Limited: ₹314.12 million

Together, 360 One Prime Limited and Tata Capital Limited account for over 70% of the outstanding principal amount. Other significant lenders include Micro Labs Limited, Sak Industries Private Ltd, and several Warmond Fiduciary Services Limited tranches.

What the numbers show

The partial release of pledge indicates a reduction in immediate collateral risk for the promoter group, even as the underlying debt remains intact. With nearly half (49.93%) of the promoter's stake still encumbered against ₹10,500 million in NCDs, the remaining pledged shares continue to serve as security for a diversified group of lenders. The high concentration of debt with 360 One Prime Limited and Tata Capital Limited suggests that any future changes in collateral requirements or debt restructuring will likely be driven by these two entities.

Thyrocare Technologies has an equity share capital of 15,91,65,315 shares with a face value of ₹10 each. The company's total diluted share capital stands at 15,96,30,252 equity shares.

Thyrocare Technologies disclosed that its promoter, Docon Technologies Private Limited, sold a significant block of equity shares in open market trades on August 13, 2026. The transaction marks a substantial reduction in the promoter group’s stake, bringing their total holding below the 60% threshold often monitored by investors for control stability.

Docon sold 1,57,69,696 equity shares during the session. This volume represents approximately 9.90% of the total paid-up equity share capital of Thyrocare. Following the settlement of these trades, Docon continues to be classified as a Promoter and holding company of Thyrocare.

Shareholding Pattern Changes

The sale has materially altered the promoter group's ownership structure. Prior to this transaction, the promoters held 60.92% of the total paid-up equity share capital. Post-transaction, this figure has declined to 51.02%.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited regarding the trade. Settlement of the transaction is being carried out in accordance with applicable laws and regulations.

Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare, signed the disclosure dated August 13, 2026.